Komatsu Koji, Sano Kei, Fukai Kota, Nakagawa Ryo, Nakagawa Takashi, Tatemichi Masayuki, Nakano Tadashi
Department of Ophthalmology, Jikei University School of Medicine, Tokyo, Japan.
Department of Preventive Medicine, School of Medicine, Tokai University, Kanagawa, Japan.
PLoS One. 2024 Dec 17;19(12):e0315752. doi: 10.1371/journal.pone.0315752. eCollection 2024.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is common in patients with obesity and diabetes and can lead to serious complications. This study aimed to evaluate fundus photographs using artificial intelligence to explore the relationships between diabetic retinopathy (DR), MASLD, and related factors. In this cross-sectional study, we included 1,736 patients with a history of diabetes treatment or glycated hemoglobin (HbA1c) levels of ≥6.5%. All participants were negative for hepatitis B surface antigen and hepatitis C virus antibody and were selected from 33,022 examinees at a health facility in Japan. Fundus photographs were analyzed using RetCAD software, and DR scores were quantified. The presence of DR was determined using two cutoffs: sensitivity (CO20) and specificity (CO50). Steatotic liver (SL) stages were assessed via ultrasound and fibrosis indices and classified into three groups: no SL (SL0), SL with low fibrosis (SL1), and SL with high fibrosis (SL2). Odds ratios (ORs) for the risk of DR associated with each SL stage were calculated using logistic regression, adjusted for age, sex, body mass index, HbA1c, C-reactive protein level, and alcohol consumption. The risk of DR was lower in the SL1 (OR: 0.63, 0.54) and SL2 (OR: 0.64, 0.77) groups compared to the SL0 group at CO20 for both the Fibrosis-4 Index (FIB-4) and the non-alcoholic fatty liver disease fibrosis score (NFS), respectively. Additionally, higher levels of cholinesterase were consistently associated with a reduced risk of DR (FIB-4: OR 0.52, NFS: OR 0.54) at CO50. This study demonstrates that MASLD was associated with a reduced risk of DR, with cholinesterase levels providing further protective effects, highlighting the need for further research into the protective mechanisms and refinement of DR evaluation techniques. The standardized AI evaluation method for DR offers a reliable approach for analyzing retinal changes.
代谢功能障碍相关脂肪性肝病(MASLD)在肥胖和糖尿病患者中很常见,并可能导致严重并发症。本研究旨在使用人工智能评估眼底照片,以探讨糖尿病视网膜病变(DR)、MASLD及相关因素之间的关系。在这项横断面研究中,我们纳入了1736例有糖尿病治疗史或糖化血红蛋白(HbA1c)水平≥6.5%的患者。所有参与者乙肝表面抗原和丙型肝炎病毒抗体均为阴性,且均选自日本一家医疗机构的33022名受检者。使用RetCAD软件分析眼底照片,并对DR评分进行量化。采用两个截断值确定DR的存在:敏感性(CO20)和特异性(CO50)。通过超声和纤维化指标评估脂肪性肝病(SL)阶段,并分为三组:无SL(SL0)、低纤维化SL(SL1)和高纤维化SL(SL2)。使用逻辑回归计算与每个SL阶段相关的DR风险的比值比(OR),并对年龄、性别、体重指数、HbA1c、C反应蛋白水平和饮酒情况进行校正。在Fibrosis-4指数(FIB-4)和非酒精性脂肪性肝病纤维化评分(NFS)的CO20时,SL1组(OR:0.63,0.54)和SL2组(OR:0.64,0.77)的DR风险均低于SL0组。此外,在CO50时,较高水平的胆碱酯酶与降低的DR风险始终相关(FIB-4:OR 0.52,NFS:OR 0.54)。本研究表明,MASLD与降低的DR风险相关,胆碱酯酶水平具有进一步的保护作用,凸显了对保护机制进行进一步研究以及完善DR评估技术的必要性。标准化的DR人工智能评估方法为分析视网膜变化提供了一种可靠的方法。